Cantor Fitzgerald Initiates Coverage of Trovagene with Buy Rating | GenomeWeb

NEW YORK (GenomeWeb News) – Cantor Fitzgerald on Monday initiated coverage of molecular diagnostics firm Trovagene with a Buy rating and a $10 price target on the company's stock.

In a research report, analyst Sung Ji Nam said that the San Diego-based firm's technology platform is capable of analyzing systemic cell-free DNA and RNA isolated from urine and could be used as a non-invasive diagnostic with applications across multiple disease areas and health conditions, including cancer, infectious diseases, transplant medicine, and prenatal diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.